Cart contains    items

Browse by molecule: [A]  [B]  [C]  [D]  [E]  [F]  [G]  [H]  [I]  [J]  [K]  [L]  [M]  [N]  [O]  [P]  [Q]  [R]  [S]  [T]  [U]  [V]  [W]  [X]  [Y]  [Z]  

Monoclonal Mouse anti Human CD33


accession:  P20138
   Size A       $
   Size B      500ug  $400
   Size C      1mg  $ 600
Clone  :  RKCD33
Isotype  :  IgG1
Catalog no. :  RMA20138
  • Western blot: This monoclonal antibody has been tested in WB analysis of human CD33 . A suitable range of concentrations of this antibody for WB detection is 0.5-2 µg/ml.
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with recombinant E. coli-derived Human CD33. 
Species reactivity:

The IgG fraction of the tissue culture supernatant was purified by Protein G affinity chromatography.

Lyophilized from sterile filtered solution at a concentration of 1mg/ml in citrate-phosphate buffer pH7.0, with 0.02%Proclin 300 as a preservative.
Endotoxin content was assayed using a LAL gel clot method.
Endotoxin level was found to be less than 0.1 ng/µg(1EU/µg).
A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers
The lyophilized antibody is stable for at least 1 year  from date of receipt at -20° C.
Upon reconstitution, this antibody can be stored in working aliquots at 2° - 8° C for one month, or at -20° C for six months without detectable loss of activity.

Avoid repeated freeze/thaw cycles.


This antibody product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.



CD33 is a 67-kDa transmembrane glycoprotein that contains one V-set and one C2-set Ig-like domain6 . It is a biomarker and therapeutic target for acute myeloid leukemia (AML). The recruitment of SHP-1 and SHP-2 by CD33 results in inhibition of tyrosine phosphorylation and Ca2+ mobilization. CD33 expression is assumed to be restricted to the myeloid lineage of immune cells. Thus, it is highly expressed on myeloid- committed cells of the bone marrow and circulating monocytes. CD33 expression is down-regulated to low levels on peripheral granulocytes and resident macrophages, and it is constitutive on DC. This expression pattern suggests a role of CD33 on myeloid differentiation and cellular function of monocyte and DC.

Related Publications:
CD33-negative acute myeloid leukemia (aml) has similar characteristics to CD33-positive disease.
Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 4129.
retargeting of activated t cells (atc) with gemtuzumab (anti-CD33) ozogamicin x anti-cd3 bispecific antibody (CD33-obi) enhances cytotoxicity directed at k562.
Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 4094.
CD33/cd10 ratios in the blast region evaluated by flow cytometry predicts the response of chronic myelogeneous leukemia to imatinib.
Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 2595.
mechanisms of discrepancy between CD33 expression and gemtuzumab ozogamicin-induced cytotoxicity in leukemia cells.
Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 4812.
the contribution of signaling endodomains to CD33-mediated killing of acute myeloid leukemia by natural killer cells transiently modified with chimeric antigen receptor.
Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 2463.

by class:
Growth factors
CD markers
Viral Antigens
by species:
Purified Polyclonal
Related Products:
product_icon_17.jpg Monoclonal Mouse anti Human CD33
product_icon_8.jpg Mouse CD33 (Siglec-3) Recombinant
product_icon_8.jpg Human CD33 (Siglec-3) Recombinant
product_icon_8.jpg Human CD33 (Siglec-3) Recombinant, Biotinylated
product_icon_7.jpg Rabbit anti CD334 (FGFR4) Polyclonal
Item name Size Quantity Price(USD) Remove
Cart Total $